查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1470890

肉瘤藥物市場：按適應症、按藥物、按銷售管道、按最終用戶 - 2024-2030 年全球預測

Sarcoma Drugs Market by Indication (Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans), Drugs (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Drug Therapy), Sales Channel, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年肉瘤治療市場規模為15.4億美元，預計2024年將達16.6億美元，2030年將達26.6億美元，複合年成長率為8.10%。

肉瘤藥物是一類專門用於治療肉瘤的藥物，肉瘤是一種罕見的異質性惡性，由骨頭、軟骨、脂肪、肌肉、血管和造血細胞等間葉組織產生。全球肉瘤發生率和盛行率不斷增加，導致對有效治療方案的需求不斷成長。政府支持癌症研究計畫的舉措使研究人員能夠探索軟組織肉瘤和骨癌等罕見惡性的新治療方法。然而，開發新治療方法的高昂成本以及醫療保健系統的相關財務負擔可能會阻礙其普及使用。研究進展提高了我們對與各種肉瘤相關的腫瘤生物學和遺傳學的理解。這些知識正在促進新的標靶治療可以精確地攻擊癌細胞，而不會顯著損害健康組織。再加上正在進行的研究創新方法（例如治療肉瘤的免疫療法和基因療法）的臨床試驗，進一步增強了該市場空間的潛力。

主要市場統計
基準年[2023] 15.4億美元
預測年份 [2024] 16.6億美元
預測年份 [2030] 26.6億美元
複合年成長率（%） 8.10%

平滑肌肉瘤的高發生率催生了開發新藥

血管肉瘤是一種罕見的侵襲性腫瘤，始於血管內壁，其治療方法包括化療、放射線治療和標靶治療。軟骨肉瘤源自治療方法細胞，是一種常見的原發性化療。皮膚纖維肉瘤（DFSP）是一種罕見的皮膚癌，其特徵是生長緩慢但復發率高。上皮樣肉瘤是軟組織肉瘤的罕見亞型，對傳統化療方案具有抗藥性。 Tazemetostat(Tazveric) 針對 EZH2 突變，並於 2020 年獲得 FDA 加速核准。卡波西氏肉瘤（KS）是由人類皰疹病毒8型感染引起的血管腫瘤。紫杉醇 (Taxol) 和脂質體阿黴素 (Doxil) 是標準治療方法。平滑肌肉瘤由平滑肌細胞發展而來，主要透過手術和化療治療。脂肪肉瘤起源於脂肪組織，分為分化良好、去分化、黏液樣/圓形細胞和多形性亞型。骨癌是兒童和青少年中最常見的原發性骨惡性，主要依賴細胞毒性化學療法。軟組織肉瘤（STS）是一種影響結締組織的異質性惡性。晚期STS病例採用化療、標靶治療及免疫治療。

根據個別藥物的基因突變情況，採用分子標靶治療肉瘤藥物進行更有針對性的治療

化療廣泛用於治療方法多種癌症，包括肉瘤。這些藥物透過針對快速分裂的細胞發揮作用，這是許多癌症的標誌。免疫療法是治療方法。人們對使用免疫療法藥物治療肉瘤越來越感興趣，特別是隨著Pembrolizumab和納武單抗等新型查核點抑制劑的出現。標靶藥物治療使用專門針對癌細胞而設計的藥物，同時最大限度地減少對正常細胞的損害。

銷售管道：藥品宅配服務的便利性增加了人們對網路銷售管道的偏好。

肉瘤藥品的線下銷售管道主要是醫院藥局、零售藥局、專科診所。許多醫療保健提供者仍然更喜歡這些傳統的個人互動管道，以確保為患者提供個人化治療。醫院藥局在向在醫院接受治療的患者分發肉瘤藥物方面發揮著重要作用。零售藥局已成為病患在醫院外憑處方箋取得肉瘤藥物的重要資訊來源。近年來，肉瘤藥物的線上銷售管道越來越受歡迎，因為它們為患者和醫療保健專業人員提供了便利和可及性。網路藥局讓患者能夠快速、謹慎地取得處方藥，提高病患用藥遵從性。

最終使用者：為醫院和診所的不同類型和階段的肉瘤患者提供多種藥物選擇

癌症研究中心專注於開發新的肉瘤治療方法、臨床試驗和個人化治療方法。需要在臨床前和早期臨床試驗中顯示出有希望結果的尖端藥物。家庭護理是指在家中而不是在醫院或診所接受治療的肉瘤患者的管理。患者出於方便和經濟原因選擇此選項。醫院和診所是肉瘤藥物最大的最終用戶部分，因為它們為患者提供綜合治療，包括手術、放射線治療和化療。根據肉瘤的類型和階段，該部分需要多種藥物。

區域洞察

美洲由於其發達的醫療基礎設施、對癌症治療選擇的高度認知以及強大的臨床實驗藥物管道而擁有先進的肉瘤藥物市場。大型製藥企業的總部均位於美國，並在該市場擁有強大的影響力。此外，政府機構和私人公司之間的合作正在加快美國食品藥物管理局(FDA) 和加拿大衛生署的藥物核准。亞洲是一個新興的肉瘤藥物市場，原因是需要有效的藥物來治療其龐大人口基數中日益成長的軟組織肉瘤 (STS) 盛行率。中國、印度、日本、韓國和澳洲等國家的新癌症治療方法的研究和發展正在迅速進展。技術的進步和早期診斷意識的提高正在推動該地區對標靶治療的需求。歐洲是一個成熟的肉瘤藥物市場，擁有成熟的參與者和歐洲藥品管理局 (EMA) 強大的法律規範，確保只有高品質的藥物才能到達患者手中。此外，多項正在進行的臨床試驗、研究合作以及與歐洲製藥公司和學術研究機構的夥伴關係提供了處於不同開發階段的臨床實驗藥物的強大管道。

FPNV定位矩陣

FPNV 定位矩陣對於評估肉瘤治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對肉瘤藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.肉瘤治療藥物市場規模及預測是多少？

2.肉瘤藥物市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.肉瘤藥物市場的技術趨勢和法規結構是什麼？

4.肉瘤治療藥物市場主要供應商的市場佔有率為何？

5.進入肉瘤藥物市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 肉瘤發生率增加以及有效治療方法的需要
      • 政府鼓勵肉瘤治療的努力
      • 政府對改良肉瘤藥物的有利核准
    • 抑制因素
      • 肉瘤的補償有限
    • 機會
      • 持續研究和開發先進的新肉瘤治療方法
      • 改善肉瘤的標靶治療和免疫治療方法
    • 任務
      • 與肉瘤抗藥性相關的問題
  • 市場區隔分析
    • 適應症：平滑肌肉瘤發生率高，開發新藥值得期待。
    • 製藥：採用標靶肉瘤療法，根據個別基因突變進行更客製化的治療
    • 銷售管道：由於處方藥送貨宅配服務的便利性，線上銷售管道越來越受到青睞。
    • 最終使用者：為醫院和診所的不同類型和階段的肉瘤患者提供多種藥物選擇
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章肉瘤藥物市場（按適應症）

  • 血管肉瘤
  • 軟骨肉瘤
  • 隆突性皮膚纖維肉瘤
  • 上皮樣肉瘤
  • 卡波西氏肉瘤
  • 平滑肌肉瘤
  • 脂肪肉瘤
  • 骨癌
  • 軟組織肉瘤

第7章肉瘤藥物治療市場

  • 化療藥物
  • 免疫治療藥物
  • 標靶藥物治療

第8章肉瘤藥物市場：依銷售管道

  • 離線
  • 線上

第9章肉瘤藥物市場：依最終使用者分類

  • 癌症研究中心
  • 居家護理
  • 醫院/診所

第10章美洲肉瘤藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太肉瘤藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲肉瘤藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 住友製藥腫瘤學獲得治療伊文氏肉瘤的孤兒藥資格
    • FDA核准Atezolizumab用於治療兒童肺泡軟組織肉瘤
    • 美國FDA 授予 Avacta 軟組織肉瘤治療孤兒藥資格
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-C002B1C996FA

[195 Pages Report] The Sarcoma Drugs Market size was estimated at USD 1.54 billion in 2023 and expected to reach USD 1.66 billion in 2024, at a CAGR 8.10% to reach USD 2.66 billion by 2030.

Sarcoma drugs are a class of medicinal products specifically designed to treat sarcomas, a rare and heterogeneous group of malignant tumors that arise from mesenchymal tissues such as bone, cartilage, fat, muscle, vascular, or hematopoietic cells. Increasing incidence and prevalence of sarcoma worldwide contribute to the rising demand for effective treatment options. Government initiatives supporting cancer research programs financially enable researchers to explore new treatment avenues for rare malignancies such as soft tissue or bone sarcomas. The high cost of developing novel therapies and the subsequent financial burden on healthcare systems can serve as a barrier to widespread adoption. Advancements in research have led to a better understanding of tumor biology and genetics associated with different forms of sarcomas. This knowledge facilitates the development of novel targeted therapies that can precisely attack cancer cells without causing significant harm to healthy tissue. Coupled with ongoing clinical trials investigating innovative approaches such as immunotherapy or gene therapy for treating sarcomas, it further enhances the potential opportunities in this market space.

KEY MARKET STATISTICS
Base Year [2023] USD 1.54 billion
Estimated Year [2024] USD 1.66 billion
Forecast Year [2030] USD 2.66 billion
CAGR (%) 8.10%

Indication: High incidence rates of leiomyosarcoma encouraging new drug development

Angiosarcoma is a rare and aggressive tumor that originates from the lining of blood vessels, and its treatment options include chemotherapy, radiation therapy, and targeted therapies. Chondrosarcoma, derived from cartilage cells, is among the common primary bone cancers for which mainstay treatment is surgery; however, when not feasible or for recurrent cases, conventional chemotherapy may be considered. Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer characterized by slow growth but high recurrence rates. Epithelioid sarcoma, a rare soft tissue sarcoma subtype, demonstrates resistance to conventional chemotherapy regimens. Tazemetostat (Tazverik) targets EZH2 mutations and gained accelerated approval from the FDA in 2020. Kaposi's sarcoma (KS) is a vascular tumor caused by infection with human herpesvirus 8. Paclitaxel (Taxol) and liposomal doxorubicin (Doxil) are the standard treatments. Leiomyosarcoma, originating from smooth muscle cells, is predominantly treated with surgery and chemotherapy agents. Liposarcoma arises from fat tissues and can be classified into well-differentiated, dedifferentiated, myxoid/round cell, or pleomorphic subtypes. Osteosarcoma, the most common primary bone malignancy in children and adolescents, mainly relies on cytotoxic chemotherapy agents. Soft tissue sarcoma (STS) represents a heterogeneous group of malignancies affecting connective tissues. Chemotherapy, targeted therapies, and immunotherapies are employed in advanced STS cases.

Drugs: Adoption of targeted sarcoma drugs for more tailored treatment based on individual genetic mutations

Chemotherapy is a widely used treatment for various types of cancer, including sarcomas. These drugs work by targeting rapidly dividing cells, which are characteristic of many cancers. Immunotherapy treatments harness the body's immune system to target and destroy cancer cells more effectively. There has been growing interest in the use of immunotherapy drugs for treating sarcomas, particularly with the advent of new checkpoint inhibitors such as pembrolizumab and nivolumab. Targeted drug therapy involves using drugs specifically designed to target cancer cells with minimal damage to normal cells.

Sales Channel: Emerging preference for online sales channel driven by their convenience for home delivery services of prescription medications

Offline sales channels for sarcoma drugs primarily consist of hospital pharmacies, retail pharmacies, and specialty clinics. Many healthcare providers still prefer these traditional channels due to the personal interactions that ensure customized treatments for patients. Hospital pharmacies play a significant role in distributing sarcoma drugs to patients undergoing treatments in hospital settings. Retail pharmacies serve as an essential source of access to sarcoma drugs for patients with prescriptions outside hospital settings. The online sales channel for sarcoma drugs has gained popularity in recent years owing to the convenience and accessibility it offers to patients and healthcare professionals. Online pharmacies allow patients to access prescription medications quickly and discreetly, improving patient adherence.

End-User: Wide range of drug options to cater to various types and stages of sarcoma patients in hospitals & clinics

Cancer research centers focus on the development of new sarcoma therapies, clinical trials, and personalized treatment approaches. They require cutting-edge drugs that have shown promising results in preclinical studies and early-phase clinical trials. Homecare refers to the management of sarcoma patients who receive treatment at home rather than in a hospital or clinic setting. Patients may choose this option due to convenience or financial considerations. Hospitals and clinics are the largest segment of end-users for sarcoma drugs, as they provide comprehensive care to patients, including surgery, radiation therapy, and chemotherapy. This segment requires a wide range of drugs to cater to different types and stages of sarcomas.

Regional Insights

The Americas have an advanced sarcoma drugs market due to its well-developed healthcare infrastructure, high awareness about cancer treatment options, and a robust pipeline of investigational drugs. Major pharmaceutical companies are headquartered in the U.S. and have a strong presence in this market. Furthermore, collaboration between government agencies and private firms has resulted in accelerated drug approvals by the U.S. Food and Drug Administration (FDA) and Health Canada. Asia is an emerging market for sarcoma drugs driven by the need for effective drugs to treat the increasing prevalence of soft tissue sarcomas (STS) among its large population base. Countries such as China, India, Japan, South Korea, and Australia are experiencing a rapid increase in R&D for new cancer therapies. Technological advancements, coupled with growing awareness about early diagnosis, have propelled the demand for targeted therapies in this region. Europe showcases a mature market for sarcoma drugs with established players and a strong regulatory framework by the European Medicines Agency (EMA), ensuring that only high-quality medicines reach patients. Furthermore, multiple ongoing clinical trials, collaborations, and partnerships between European pharmaceutical companies and academic research institutions have led to a robust pipeline of investigational drugs in various phases of development.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Sarcoma Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Sarcoma Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Sarcoma Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AgonOx, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, Avacta Life Sciences Limited, Baxter International Inc., Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ipsen Pharma, Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Limited, TRACON Pharmaceuticals, Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Sarcoma Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Angiosarcoma
    • Chondrosarcoma
    • Dermatofibrosarcoma Protuberans
    • Epithelioid Sarcoma
    • Kaposi's Sarcoma
    • Leiomyosarcoma
    • Liposarcoma
    • Osteosarcoma
    • Soft Tissue Sarcoma
  • Drugs
    • Chemotherapy Drugs
      • Cisplatin
      • Docetaxel
      • Doxorubicin
      • Etoposide
      • Gemcitabine
      • Ifosfamide
      • Paclitaxel
      • Trabectedin
      • Vincristine
    • Immunotherapy Drugs
      • Atezolizumab
      • Pembrolizumab
    • Targeted Drug Therapy
      • Entrectinib
      • Pazopanib
      • Sorafenib
      • Sunitinib
      • Tazemetostat
  • Sales Channel
    • Offline
      • Hospitals Pharmacies
      • Retail Pharmacies
    • Online
  • End-User
    • Cancer Research Center
    • Homecare
    • Hospital & clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Sarcoma Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Sarcoma Drugs Market?

3. What are the technology trends and regulatory frameworks in the Sarcoma Drugs Market?

4. What is the market share of the leading vendors in the Sarcoma Drugs Market?

5. Which modes and strategic moves are suitable for entering the Sarcoma Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of sarcoma and the need for effective treatment options
      • 5.1.1.2. Government initiatives encouraging the treatment of sarcoma
      • 5.1.1.3. Favorable government approvals for improved sarcoma drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursements available for sarcoma
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for advanced and new sarcoma drugs
      • 5.1.3.2. Improvements in targeted and immunotherapy approaches for sarcoma
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with drug resistance in sarcomas
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication: High incidence rates of leiomyosarcoma encouraging new drug development
    • 5.2.2. Drugs: Adoption of targeted sarcoma drugs for more tailored treatment based on individual genetic mutations
    • 5.2.3. Sales Channel: Emerging preference for online sales channel driven by their convenience for home delivery services of prescription medications
    • 5.2.4. End-User: Wide range of drug options to cater to various types and stages of sarcoma patients in hospitals & clinics
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Sarcoma Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Angiosarcoma
  • 6.3. Chondrosarcoma
  • 6.4. Dermatofibrosarcoma Protuberans
  • 6.5. Epithelioid Sarcoma
  • 6.6. Kaposi's Sarcoma
  • 6.7. Leiomyosarcoma
  • 6.8. Liposarcoma
  • 6.9. Osteosarcoma
  • 6.10. Soft Tissue Sarcoma

7. Sarcoma Drugs Market, by Drugs

  • 7.1. Introduction
  • 7.2. Chemotherapy Drugs
  • 7.3. Immunotherapy Drugs
  • 7.4. Targeted Drug Therapy

8. Sarcoma Drugs Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Sarcoma Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Cancer Research Center
  • 9.3. Homecare
  • 9.4. Hospital & clinics

10. Americas Sarcoma Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Sarcoma Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Sarcoma Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment
    • 13.3.2. FDA approves atezolizumab for alveolar soft part sarcoma in pediatric patients
    • 13.3.3. US FDA grants Orphan Drug status to Avacta's drug for soft tissue sarcoma
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. SARCOMA DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. SARCOMA DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SARCOMA DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. SARCOMA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. SARCOMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SARCOMA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANGIOSARCOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANGIOSARCOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DERMATOFIBROSARCOMA PROTUBERANS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DERMATOFIBROSARCOMA PROTUBERANS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EPITHELIOID SARCOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EPITHELIOID SARCOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI'S SARCOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI'S SARCOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CISPLATIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DOXORUBICIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DOXORUBICIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ETOPOSIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ETOPOSIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GEMCITABINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GEMCITABINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IFOSFAMIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IFOSFAMIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PACLITAXEL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TRABECTEDIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TRABECTEDIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VINCRISTINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VINCRISTINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ENTRECTINIB, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ENTRECTINIB, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PAZOPANIB, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PAZOPANIB, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SORAFENIB, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SORAFENIB, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUNITINIB, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUNITINIB, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TAZEMETOSTAT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TAZEMETOSTAT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 76. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 77. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 78. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 79. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 80. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 81. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 82. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 83. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 84. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 85. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 86. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 87. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER RESEARCH CENTER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 88. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER RESEARCH CENTER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 89. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 90. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 91. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 92. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 93. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 94. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 95. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 96. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 97. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 98. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 99. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 100. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 101. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 102. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 103. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. AMERICAS SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 106. AMERICAS SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 107. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 110. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 111. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 114. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 115. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 116. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 117. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 118. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 119. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 120. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 121. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 124. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 125. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. BRAZIL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 128. BRAZIL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 129. BRAZIL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 130. BRAZIL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 131. BRAZIL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 132. BRAZIL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 133. BRAZIL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 134. BRAZIL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 135. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 136. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 137. BRAZIL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. BRAZIL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. BRAZIL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 140. BRAZIL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 141. BRAZIL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. BRAZIL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. CANADA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. CANADA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. CANADA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 146. CANADA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 147. CANADA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 148. CANADA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 149. CANADA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 150. CANADA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 151. CANADA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 152. CANADA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 153. CANADA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. CANADA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. CANADA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 156. CANADA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 157. CANADA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 158. CANADA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 159. MEXICO SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. MEXICO SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. MEXICO SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 162. MEXICO SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 163. MEXICO SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 164. MEXICO SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 165. MEXICO SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 166. MEXICO SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 167. MEXICO SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 168. MEXICO SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 169. MEXICO SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. MEXICO SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. MEXICO SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 172. MEXICO SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 173. MEXICO SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. MEXICO SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 178. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 179. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 180. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 181. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 182. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 183. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 184. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 185. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 188. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 189. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 190. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 191. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 192. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 211. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 212. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 213. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 214. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 215. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 216. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 217. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 218. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 219. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 220. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 221. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 222. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 223. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 224. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 225. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. CHINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 228. CHINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 229. CHINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 230. CHINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 231. CHINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 232. CHINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 233. CHINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 234. CHINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 235. CHINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 236. CHINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 237. CHINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. CHINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. CHINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 240. CHINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 241. CHINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. CHINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. INDIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 244. INDIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 245. INDIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 246. INDIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 247. INDIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 248. INDIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 249. INDIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 250. INDIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 251. INDIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 252. INDIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 253. INDIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 254. INDIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 255. INDIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 256. INDIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 257. INDIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 258. INDIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 259. INDONESIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 260. INDONESIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 261. INDONESIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 262. INDONESIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 263. INDONESIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 264. INDONESIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 265. INDONESIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 266. INDONESIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 267. INDONESIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 268. INDONESIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 269. INDONESIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 270. INDONESIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 271. INDONESIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 272. INDONESIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 273. INDONESIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. INDONESIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. JAPAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 276. JAPAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 277. JAPAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 278. JAPAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 279. JAPAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 280. JAPAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 281. JAPAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 282. JAPAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 283. JAPAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 284. JAPAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 285. JAPAN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 286. JAPAN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 287. JAPAN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 288. JAPAN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 289. JAPAN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 290. JAPAN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 291. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 292. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 293. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 294. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 295. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 296. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 297. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 298. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 299. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 300. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 301. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 302. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 303. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 304. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 305. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 306. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 307. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 308. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 309. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 310. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 311. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 312. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 313. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 314. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 315. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 316. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 317. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 318. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 319. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 320. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 321. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 322. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 323. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 324. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 325. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 326. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 327. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 328. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 329. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 330. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 331. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 332. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 333. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 334. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 335. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 336. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 337. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 338. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 339. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 340. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 341. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 342. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 343. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 344. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 345. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 346. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 347. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 348. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 349. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 350. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 351. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 352. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 353. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 354. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 355. TAIWAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 356. TAIWAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 357. TAIWAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 358. TAIWAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 359. TAIWAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 360. TAIWAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 361. TAIWAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 362. TAIWAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 363. TAIWAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 364. TAIWAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 365. TAIWAN SARCOMA DRUGS MARK